The Swiss Bridge Foundation, established in 1997, is a private charitable foundation that seeks support for worldwide cancer research from financially independent individuals and corporations. The Foundation works in association with the Swiss Cancer League, the Swiss Cancer Research Foundation and the International Union Against Cancer (UICC) to support high quality cancer research in Europe.
The 2019 call for the Swiss Bridge Award is seeking proposals from young investigators at academic and cancer research institutions in Europe for research focusing on this year's theme: 'immune cell therapy'. Eligible projects include all types of immune-cell therapies, such as chimeric antigen receptor T-cell (CAR T-cell) therapy, tumour-infiltrating lymphocytes (TILs) therapy, and dendritic cell vaccine therapy.
Young investigators are considered by the Swiss Bridge Foundation to be early stage researchers under the age of 45 who hold a PhD or MD and have obtained an independent position at a hospital, university or research institute in Europe - this includes junior group leaders, assistant professors, lecturers, and scientists establishing their own research group or equivalent.
Up to three projects will receive funding of up to 500,000 Swiss Francs over three years. Following the intent to submit stage, between six and eight investigators will be shortlisted and invited to submit a detailed research application by mid-June 2019. The winners will be invited to a ceremony to be held in Zurich in October 2019.
The deadline for notes of intent is 30 April 2019.
More information about this research funding opportunity and the application process is available on the RESEARCHconnect funding information platform. RESEARCHconnect provides up-to-the minute content, insight and analysis on research funding news and policy. To find out more about how RESEARCHconnect can keep you in the know, and subscription fees, contact us today.